January 8, 2026 – National Institutes of Health (NIH) released the following: ...

For high-risk patients, the method could offer a safer alternative to open-heart surgery.

After coronary artery bypass grafting (CABG), evolocumab did not reduce saphenous vein graft disease rates at 2 years compared with placebo, according to late-breaking research presented in a Hot Line ...

A heart attack survivor is the first person to receive groundbreaking gene therapy which aims to prevent a major heart ...

A novel device called venous external support (VEST) may lead to increased longevity and durability of saphenous (leg) vein grafting during coronary artery bypass surgery, according to a new trial ...

CHICAGO, IL—For patients undergoing coronary artery bypass grafting, use of radial arteries leads to less MACE over 15 years compared with using either right internal thoracic artery (RITA) or ...

Scott Johnstone (left), an associate professor with the Fralin Biomedical Research Institute, and Mark Joseph, a cardiothoracic surgeon with Carilion Clinic, led a study published in the Journal of ...

During a coronary artery bypass, the diseased sections of your coronary arteries are bypassed with healthy artery or vein grafts to increase blood flow to the heart muscle tissue. This procedure is ...

A retired HGV driver was the first person in the world to take part in a clinical trial to extend the lifespan of blood ...

The goal of coronary artery bypass grafting (CABG) is to improve blood flow to your heart. The heart is a muscle about the size of your fist. Your heart pumps blood and oxygen to all of the organs and ...

John MacDonald, 73, took part in a clinical trial using gene therapy to extend the lifespan of blood vessels in the heart ...